Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 2, 2000, Pages 214-217

  Komiyama, Atsushi ^a   Arai, Hiroshi ^b   Kijima, Masanori ^b   Hirayama, Keizo ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Corticosteroids; Direct facilitatory effect; Extraocular muscles; Myasthenia gravis

Indexed keywords

ACETYLCHOLINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE;

ACETYLCHOLINE RELEASE; ADAPTATION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; EXTRAOCULAR MUSCLE; FATIGUE; FEMALE; HUMAN; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; PTOSIS;

ACETYLCHOLINE; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; BLEPHAROPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; OPHTHALMOPLEGIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034095913     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.2.214     Document Type: Article

References (18)

1. Lisak RP, Barchi RL. Myasthenia gravis. Philadelphia: WB Saunders, 1982.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-810.
3. Warmolts JR, Engel WK. Benefit from alternate day prednisolone in myasthenia gravis. N Engl J Med 1972;286: 17-20.
4. Wilson RW, Ward MD, Johns TR. Corticosteroids. A direct effect at the neuromuscular junction. Neurology 1974;24: 1091-5.
5. Kim YI, Goldner MM, Sanders DB. Short-term effects of prednisolone on neuromuscular transmission in normal rats and those with experimental autoimmune myasthenia gravis. J Neurol Sci 1979;41:223-34.
6. Miller RG, Miller-Brown HS, Mirka A. Prednisolone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986;36:729-32.
7. Porter JD, Baker RS. Muscles of a different "color": the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Neurology 1996;46:30-7.
8. Komiyama A, Kamo I, Furukawa S, et al. Antibodies against saline-soluble components of skeletal muscle in myasthenia gravis. J Neurol 1988;235:207-13.
9. Saavedra J, Femminini R, Kochen S, et al. A cold test for myasthenia gravis. Neurology 1979;29:1075.
10. Gorelick PB, Rosenberg M, Pagano RJ. Enhanced ptosis in myasthenia gravis. Arch Neurol 1981;38:531.
11. Besinger UA, Toyka KV, Hömberg M, et al. Myasthenia gravis: long term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:136-21.
12. Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996;40:645-54.
13. Panegyres PK, Squier M, Mills KR, et al. Acute myopathy associated with large patenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56: 702-4.
14. Grossie J, Albuquerque EX. Extensor muscle responses to triamcinolone. Arch Neurol 1978;58:435-45.
15. MacLennan C, Beeson D, Buijis A-M, et al. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997; 41:423-31.
16. Porter JD, Burns LA, May PJ. Morphological substrate for eyelid movements: innervation and structure of primate levator palpebrae superioris and orbicularis oculi muscles. J Comp Neurol 1989;287:64-81.
17. Spencer RF, Porter JD. Structural organization of the extraocular muscles. In: Büttner-Ennever JA, eds. Reviews in oculomotor research. Vol 2. Neuroanatomy of the oculomotor system. New York: Elsevier, 1988:33-79.
18. Komiyama A, Toda H, Johkura K. Edrophonium-induced macrosaccadic oscillations in myasthenia gravis. Ann Neurol 1999;45:522-5.